Bioventix PLC (AIM:BVXP)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 88.82M |
| Revenue (ttm) | 12.54M |
| Net Income (ttm) | 7.44M |
| Shares Out | 5.22M |
| EPS (ttm) | 1.41 |
| PE Ratio | 12.10 |
| Forward PE | n/a |
| Dividend | 1.50 (8.82%) |
| Ex-Dividend Date | Apr 9, 2026 |
| Volume | 33,637 |
| Average Volume | 16,136 |
| Open | 1,602.50 |
| Previous Close | 1,700.00 |
| Day's Range | 1,600.00 - 1,700.00 |
| 52-Week Range | 1,300.00 - 3,020.00 |
| Beta | 0.48 |
| RSI | 51.26 |
| Earnings Date | Jun 26, 2026 |
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environ... [Read more]
Financial Performance
In fiscal year 2025, Bioventix's revenue was 13.12 million, a decrease of -3.61% compared to the previous year's 13.61 million. Earnings were 7.58 million, a decrease of -6.33%.
Financial StatementsNews
AIM Market Roundup: Angle, Coyngar, Light Science Technologies
Angle, Coyngar, Light Science Technologies are today's top risers, while BioVentix, Great Western Mining take the biggest fall on AIM